Skip to content

Clinical trials

Pulmonary Arterial Hypertension trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Arterial Hypertension Country / region: Germany Clear all

119 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20031
20042
20051
20063
20074
20086
20095
20107
20118
20123
20133
20144
20154
20164
20177
201811
20199
20203
202111
20225
20237
20247
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed69
Terminated29
Recruiting9
Active, not recruiting5
Enrolling by invitation3
Unknown status3
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Actelion22
Novartis Pharmaceuticals11
Bayer10
United Therapeutics8
Bial - Portela C S.A.6
University of Giessen6
Heidelberg University5
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA4
GlaxoSmithKline4
Merck Sharp & Dohme LLC4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Arterial Hypertension119
Hypertension, Pulmonary48
Familial Primary Pulmonary Hypertension7
Eisenmenger Complex5
Hypertension5
Connective Tissue Diseases3
Lung Diseases3
Vascular Diseases3
Cardiovascular Diseases2
Cough2

Trials

Showing 76 to 100 of 119. Each trial links to its page on Pharma Observatory.

19 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.